Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Corient Private Wealth LLC

Corient Private Wealth LLC boosted its position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 161.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,182,699 shares of the company's stock after buying an additional 730,699 shares during the period. Corient Private Wealth LLC owned approximately 0.53% of Sana Biotechnology worth $1,928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of SANA. FMR LLC grew its holdings in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company's stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the period. State Street Corp raised its holdings in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company's stock valued at $27,570,000 after purchasing an additional 269,274 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock worth $13,175,000 after buying an additional 276,055 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Sana Biotechnology by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock worth $1,722,000 after buying an additional 8,666 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Sana Biotechnology by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 336,828 shares of the company's stock valued at $549,000 after acquiring an additional 9,905 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

NASDAQ:SANA traded down $0.14 during mid-day trading on Friday, hitting $1.71. 2,756,809 shares of the company's stock traded hands, compared to its average volume of 3,105,141. The firm's 50 day simple moving average is $2.83 and its 200 day simple moving average is $3.07. The company has a market cap of $384.79 million, a PE ratio of -1.22 and a beta of 1.63. Sana Biotechnology, Inc. has a 1 year low of $1.52 and a 1 year high of $10.50.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Fmr Llc sold 290,912 shares of the business's stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 31.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SANA shares. Jefferies Financial Group began coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a "buy" rating and a $7.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, March 18th. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th. Finally, TD Cowen raised Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.